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Background: The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is
crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown to
enhance drug delivery to bones.
Methods: In this study six-L aspartic acids (D6) were inserted into the AAV2 capsid protein sequence between
amino acid residues 587 and 588. 129SVE mice were injected with double-stranded wild-type- (WT-) or D6-AAV2
mCherry expression vectors (3.24 x 1010 vg per animal) via the superficial temporal vein within 24 hours of birth.
Results: Fluorescence microscopy and quantitative polymerase chain reaction confirmed higher levels of mCherry
expression in the paraspinal and gluteus muscles in the D6-AAV2 injected mice. The results revealed that although
D6-AAV2 was less efficient in the transduction of immortalized cells stronger mCherry signals were detected over
the spine and pelvis by live imaging in the D6-AAV2-injected mice than were detected in the WT-AAV2-injected
mice. In addition, D6-AAV2 lost the liver tropism observed for WT-AAV2.
Conclusions: An acidic oligopeptide displayed on AAV2 improves axial muscle tropism and decreases liver tropism
after systemic delivery. This modification should be useful in creating AAV vectors that are suitable for gene therapy
for diseases involving the proximal muscles.
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Adeno-associated virus serotype 2 (AAV2) is a non-
pathogenic parvovirus that is commonly used in human
gene therapy [1]. The advantages of AAV2 vectors
include the ability to infect non-dividing cells, sustained
gene expression, and low immune responses [2,3], but
excessive liver tropism of these vectors and inefficient
transduction of other organs after systemic injection is
problematic. Other AAV serotypes have altered tissue
tropism and higher infectivity than AAV2 [4,5]. However,* Correspondence: hwuwlntu@ntu.edu.tw
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reproduction in any medium, provided the orspecific targeting is still a problem; for example, the
transduction of the liver can induce innate immune
responses and toxicity [6,7]. Currently, studies focused
on either genetic [8] or biochemical modifications [9] of
the AAV capsid protein are ongoing.
Membrane-associated heparan sulfate proteoglycan
(HSPG) is a receptor for the AAV2 virus [10]. The
HSPG-binding motif is composed of the amino acid resi-
dues R484, R487, K532, R585, and R588 of the capsid
protein (according to the numbering for VP1) [11]. The
insertion of an oligopeptide between residues 587 and
588 disrupts the HSPG-binding motif [12] and has been
shown to retarget AAV2 vectors to the angiogenic vas-
culature, diaphragm, heart, or endothelial cells [13-15].
The limited delivery of drugs to bones has been a bar-
rier in the treatment of diseases of the skeletal system.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with an oligopeptide composed of six or more acidic
amino acids (L-aspartate or L-glutamate) bound strongly
to hydroxyapatite, a major component of bones [16].
Oligopeptide-conjugated enzymes were later developed
to treat diseases including hypophosphatasia [17] and
mucopolysaccharidosis type IV [18]. An AAV8 vector
expressing deca-aspartate-tagged tissue-nonspecific alka-
line phosphatase has also been used to treat hypopho-
sphatasia [19].
In this study, we inserted six L-aspartic acids (D6)
between residues 587 and 588 of the AAV2 capsid pro-
tein. We demonstrate that D6-AAV2 exhibits improved
axial muscle tropism and decreased liver tropism after
systemic delivery.
Methods
Plasmids and cell cultures
A nucleotide sequence (5'-GACGATGACGATGACG
AT) encoding six L-aspartic acids (D6) was inserted be-
tween amino acid residues 587 and 588 of the AAV2 cap
gene in the pAAV-RC plasmid (Agilent, Santa Clara,
CA) using the QuikChange Lightning Site-DirectedFigure 1 Production of D6-AAV2 vectors and in vitro infection assay.
proteins. The picture shows capsid proteins VP1, VP2, and VP3. The three c
but had higher molecular weights than those of WT-AAV2. (B) Heparin aga
were loaded onto a heparin agarose column, the D6-AAV2 viruses did not
(C) Infectivity in cells shown by the mCherry red fluorescence. HT1080 cells
chondrocytes (d and h) were infected with either WT- or D6-AAV2. Compa
showed either weak fluorescence (HEK293) or no fluorescence (all other typMutagenesis Kit (Agilent). Double-stranded WT- and
D6-AAV2 mCherry expression vectors were produced at
the Powell Gene Therapy Center using methods previ-
ously reported [11]. HEK293 cells were harvested and
purified using a discontinuous iodixanol gradient and
concentrated in an ApolloW concentrator with a final
volume of 500 μl. Viral genome (vg) titers were deter-
mined using quantitative real-time PCR (qPCR) with pri-
mers directed against the CMV promoter region [20].
The capsid proteins were analyzed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and silver
staining. The heparan binding capability was measured by
loading a known amount of WT- (4.95× 1011 vg/ml) or
D6-AAV2 (3.90 × 1011) into a heparin agarose column for
chromatography [21]. The flowthrough and eluate were
collected, and qPCR was performed to determine the viral
genome titer. HT1080 cells, HEK293 cells, C2C12 cells,
and human chondrocytes were seeded in 96-well plates
and reached 80% confluence 24 hours later. Cells were
infected with the WT- or D6-AAV2 vector at a multipli-
city of infection (MOI) of 1,000 for HEK293 cells, 10,000
for C2C12 cells, and 20,000 for HT1080 cells and human
chondrocytes. HEK293 and C2C12 cells were infected in(A) Electrophoresis and silver staining for the WT- and D6-AAV2 capsid
apsid proteins of D6-AAV2 were present at similar relative quantities
rose chromatography. When known amounts of WT- and D6-AAV2
bind to the column and were present in the flowthrough fraction.
(a and e), HEK293 cells (b and f), C2C12 cells (c and g), and human
red with the WT-AAV2-infected cells, the D6-AAV2-infected cells
es of cells).
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infectivity assay protocol for HEK293 cells [21]. Forty-
eight hours after infection, the numbers of mCherry-
positive cells were counted by fluorescence microscopy.
Animal studies
Neonatal 129SVE mice were injected with the WT- or
D6-AAV2 vector (n = 7 each group with 3.24 × 1010 vg
per animal in 30μL) within 24 hours of birth via the
superficial temporal vein using a 29 G needle. Live imag-
ing was performed on anesthetized mice (n = 3 each
group, monthly up to 4 months after injection, under 2%
isoflurane in 100% O2) using the Xenogen IVISW
Spectrum in vivo Bioluminescence and Fluorescent
Imager (Caliper Life Sciences, Hopkinton, MA), and
mCherry signals were obtained with excitation/emission
wavelengths of 570/620 nm. Mice were euthanizedFigure 2 IVIS live imaging for three mice at four months after injectio
injected mouse is in the middle, and the WT-AAV2-injected mice is on the
removed. (C) Dissected gluteus muscles. (D) Dissected paraspinal muscles.
was observed in the D6-AAV2-injected mouse over the spine and pelvis (Aunder isoflurane anesthesia prior to tissue collection via
thoracotomy and removal of the heart. For direct fluor-
escence microscopy, mouse tissue was fixed in 4% para-
formaldehyde after direct dissection of the tissue,
embedded in OCT and cut into 6–12 μm sections (Leica
CM1850 cryotome, Houston, TX, USA). A Chroma
51006 FITC/Texas Red dual-band filter was used to
eliminate autofluorescence (Chroma, Bellows Falls, VT).
The tissues were also stained with 4’,6-diamidino-
2-phenylindole (DAPI). Tissue samples from another
4 mice in each group were also harvested for DNA
extraction using the DNeasy Blood & Tissue kit (QIAGEN,
Valencia, CA, USA) 4 weeks after injection. The total vg
copy numbers in the tissues were determined by qPCR
and expressed as vg per μg DNA. All animal studies were
approved and performed in accordance with guidelines
of the University of Florida Institutional Animal Caren. The D6-AAV2-injected mouse is on the left, the lactated Ringer-
right. (A) An image with the fur removed. (B) An image with the skin
A scale bar was placed on each image. Stronger mCherry fluorescence
and B) and over the dissected gluteus (C) and paraspinal (D) muscles.
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National Taiwan University College of Medicine and
College of Public Health Institutional Animal Care and
Use Committee (IACUC No. 20110265).
Statistical analysis
Data are presented as the mean ± SD in each figure.
Statistical analyses were performed using the SPSS (Stat-
istical Package for the Social Sciences) statistical pack-
age, version 11.5. The Mann–Whitney Rank Test was
used for comparisons of different groups. A p value less
than 0.05 was considered statistically significant.
Results and discussion
Production of the D6-AAV2 vector and its infectivity
in cells
D6-AAV2 was produced with a vg titer similar to that of
WT-AAV2 (1.22x1011 and 1.08x1011 vg/ml, respectively,
from 1 cell factory). Silver staining showed similar rela-
tive quantities of the VP1, VP2, and VP3 capsid proteins,
but the capsid proteins from D6-AAV2 had higher
molecular weights than those fromWT-AAV2 (Figure 1A).
D6-AAV2 lost its heparin-binding ability (Figure 1B),
and therefore a heparin-agarose column could not be
used for vector preparation. D6-AAV2 also lost the abil-
ity to infect cultured HT1080 cells, HEK293 cells, C2C12
cells, and human chondrocytes, which could all be
infected by WT-AAV2 (Figure 1C).Figure 3 Direct fluorescence microscopy for sections of the paraspina
a control mouse (B and E), and a WT-AAV2-injected mouse (C and F).
band filter, was stronger in muscles from the D6-AAV2-injected mouse.Tropism of D6-AAV2
IVIS live imaging was performed on mice monthly up to
four months after injection. The results revealed that the
mCherry signals were stronger over the spine and pelvis
in the D6-AAV2-injected mice than in the WT-AAV2-
injected mice (Figure 2A). Because 129SVE mice had
dark fur, we needed to remove the fur before IVIS
imaging. After we euthanized the mice and removed the
skin, we repeated the IVIS imaging to confirm the
mCherry signals (Figure 2B). We further demonstrated
that the mCherry signals were from muscles and not
bones by separating the gluteus (Figure 2C) and para-
spinal muscles (Figure 2D) from the bones. By direct
fluorescence microscopy, we could see strong mCherry
red fluorescence in the paraspinal muscle sections in the
D6-AAV2-injected mice (Figure 3A). Signals over the
gluteus muscles were also visible (Figure 3D). However,
there was no mCherry red fluorescence in either the
WT-AAV2-injected mice or the control mice (Figure 3).
qPCR quantification demonstrated much higher AAV2
copy numbers in the paraspinal and gluteus muscles and
higher copy numbers in the diaphragm, quadriceps, tibi-
alis anterior, and iliopsoas muscles in the D6-AAV2-
injected mice than in the WT-AAV2-injected mice
(Figure 4). In contrast, the copy numbers were lower in
liver, spleen, heart, and brain in the D6-AAV2-injected
mice (Figure 4). The study by Yu et al. demonstrated
that the insertion of amino acids into the capsid ofl and gluteus muscles from a D6-AAV2-injected mouse (A and D),
Red mCherry fluorescence, visualized using a FITC/Texas Red dual-
Figure 4 Biodistribution of the WT- (n = 4) and D6-AAV2 (n= 4) vectors in mice four weeks after injection. The vg copy numbers are
shown on a log scale on the left. The error bars indicate one standard deviation. *P< 0.05.
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muscles, especially the lung, heart, and diaphragm, in
adult mice [13]. Although D6-AAV2 also demonstrated
higher tropism for muscle, the distributions of the
muscle groups are different. This difference might due to
the different effects of the insertions on tropism. In the
study of Yu et al., the muscle-targeting peptide they
inserted possessed neutral charges, whereas our D6 pep-
tide had negative charges. The negative charges might
lead to binding to hydroxyapatite in the bone. Addition-
ally, the mice that we injected were in the neonatal
period. The age of the mice might also have contributed
to the different results.
Proposed mechanisms for the altered tropism
The insertion of six L-aspartic acids into the capsid pro-
tein enhances AAV2 axial and hind limb muscle tropism
and decreases liver tropism. It is known that the inser-
tion of oligopeptides after amino acid residue 587 dis-
rupts the HSPG-binding motif of AAV2 [12], leading to
liver detargeting. However, acidic oligopeptides should
bind to hydroxyapatite and lead to bone targeting [16].
It is possible that the binding between the acidic oligo-
peptides and hydroxyapatite in large bones including the
vertebrae and pelvis only temporarily retains the virus.
Because D6-AAV2 does not readily infect the bone
marrow cellular components, the viruses ultimately leave
the bones and infect the nearby muscles.
Future applications
Many hereditary myopathies, including Duchenne mus-
cular dystrophy, limb girdle muscular dystrophy, and
adult-onset Pompe disease, preferentially involve theproximal and trunk muscles [22]. Therefore, the D6
modification would be helpful in designing viral vectors
to treat those diseases. Because of the low yield of the
AAV2 vector, we were not able to test D6-AAV2 in adult
mice at the same dose per body weight as we used in the
neonatal mice. There are already new AAV serotypes
that have much higher transduction efficiencies than
AAV2, such that addition of the D6 modification to
those AAV vectors may further increase their relative
muscle tropism and allow these vectors to be used in a
safer manner in the treatment of hereditary myopathies.
Conclusion
In this study, we demonstrated that an acidic oligopep-
tide displayed on AAV2 improves axial muscle tropism
and decreases liver tropism after systemic delivery. This
modification should be useful in creating AAV vectors
suitable for gene therapy for diseases involving the prox-
imal muscles. Future studies of the targeting effects of
different acidic oligopeptides in conjunction with differ-
ent AAV serotypes may be helpful to expand the applica-
tions of AAVs.
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